Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow's Feet)
Both studies met their primary endpoints with significantly higher response than placebo after one month for both frown lines and crow's feet Results showed rapid onset of action with median
Source: finanznachrichten.de